707 related articles for article (PubMed ID: 28944694)
1. Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.
Liu S; Feng X; Jin R; Li G
Expert Opin Drug Deliv; 2018 Feb; 15(2):173-184. PubMed ID: 28944694
[TBL] [Abstract][Full Text] [Related]
2. Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke.
Ma H; Jiang Z; Xu J; Liu J; Guo ZN
Drug Deliv; 2021 Dec; 28(1):357-371. PubMed ID: 33517820
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke.
Zamanlu M; Farhoudi M; Eskandani M; Mahmoudi J; Barar J; Rafi M; Omidi Y
J Drug Target; 2018 Feb; 26(2):95-109. PubMed ID: 28796540
[TBL] [Abstract][Full Text] [Related]
4. Role of tissue plasminogen activator in acute ischemic stroke.
Hatcher MA; Starr JA
Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
[TBL] [Abstract][Full Text] [Related]
5. Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
Eissa A; Krass I; Bajorek BV
J Clin Pharm Ther; 2012 Dec; 37(6):620-9. PubMed ID: 22708668
[TBL] [Abstract][Full Text] [Related]
6. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic.
Yepes M; Roussel BD; Ali C; Vivien D
Trends Neurosci; 2009 Jan; 32(1):48-55. PubMed ID: 18963068
[TBL] [Abstract][Full Text] [Related]
7. Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke.
Hu J; Huang S; Zhu L; Huang W; Zhao Y; Jin K; ZhuGe Q
ACS Appl Mater Interfaces; 2018 Oct; 10(39):32988-32997. PubMed ID: 30192506
[TBL] [Abstract][Full Text] [Related]
8. [Recent progress in developing of thrombolytic agents for ischemic stroke].
Xu Y; Chen S; Chen D; Peng S; Cheng Y; Li J; Li Y; Jiang L; Yuan C; Huang M
Sheng Wu Gong Cheng Xue Bao; 2020 Oct; 36(10):2029-2039. PubMed ID: 33169568
[TBL] [Abstract][Full Text] [Related]
9. Intravenous thrombolysis for acute ischemic stroke in Asia.
Sharma VK; Ng KW; Venketasubramanian N; Teoh HL; Chan BP
Expert Rev Neurother; 2012 Feb; 12(2):209-17. PubMed ID: 22288676
[TBL] [Abstract][Full Text] [Related]
10. Current status of intravenous thrombolysis for acute ischemic stroke in Asia.
Sharma VK; Ng KW; Venketasubramanian N; Saqqur M; Teoh HL; Kaul S; Srivastava PM; Sergentanis T; Suwanwela N; Nguyen TH; Lawrence Wong KS; Chan BP
Int J Stroke; 2011 Dec; 6(6):523-30. PubMed ID: 22111797
[TBL] [Abstract][Full Text] [Related]
11. Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants--Case Series and Systematic Review of Reported Cases.
Shahjouei S; Tsivgoulis G; Bavarsad Shahripour R; Jones GM; Alexandrov AV; Zand R
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2685-93. PubMed ID: 26542821
[TBL] [Abstract][Full Text] [Related]
12. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group.
Heuschmann PU; Berger K; Misselwitz B; Hermanek P; Leffmann C; Adelmann M; Buecker-Nott HJ; Rother J; Neundoerfer B; Kolominsky-Rabas PL; ;
Stroke; 2003 May; 34(5):1106-13. PubMed ID: 12663875
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activation and thrombolysis for ischemic stroke.
Medcalf RL; Davis SM
Int J Stroke; 2012 Jul; 7(5):419-25. PubMed ID: 22463085
[TBL] [Abstract][Full Text] [Related]
14. Barriers to administering intravenous tissue plasminogen activator (tPA) for acute ischemic stroke in the emergency department: A cross-sectional survey of stroke centers.
Hargis M; Shah JN; Mazabob J; Rao CV; Suarez JI; Bershad EM
Clin Neurol Neurosurg; 2015 Aug; 135():79-84. PubMed ID: 26047090
[TBL] [Abstract][Full Text] [Related]
15. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.
Mehta RH; Cox M; Smith EE; Xian Y; Bhatt DL; Fonarow GC; Peterson ED;
Stroke; 2014 Aug; 45(8):2263-9. PubMed ID: 25070958
[TBL] [Abstract][Full Text] [Related]
16. Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.
Chapman SN; Mehndiratta P; Johansen MC; McMurry TL; Johnston KC; Southerland AM
Vasc Health Risk Manag; 2014; 10():75-87. PubMed ID: 24591838
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Cheng JW; Zhang XJ; Cheng LS; Li GY; Zhang LJ; Ji KX; Zhao Q; Bai Y
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):381-390. PubMed ID: 29111341
[TBL] [Abstract][Full Text] [Related]
18. Progress in Intravenous Thrombolytic Therapy for Acute Stroke.
Marshall RS
JAMA Neurol; 2015 Aug; 72(8):928-34. PubMed ID: 26030910
[TBL] [Abstract][Full Text] [Related]
19. The use and misuse of thrombolytic therapy within the Veterans Health Administration.
Keyhani S; Arling G; Williams LS; Ross JS; Ordin DL; Myers J; Tyndall G; Vogel B; Bravata DM
Med Care; 2012 Jan; 50(1):66-73. PubMed ID: 22182924
[TBL] [Abstract][Full Text] [Related]
20. Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-D-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis.
Macrez R; Obiang P; Gauberti M; Roussel B; Baron A; Parcq J; Cassé F; Hommet Y; Orset C; Agin V; Bezin L; Berrocoso TG; Petersen KU; Montaner J; Maubert E; Vivien D; Ali C
Stroke; 2011 Aug; 42(8):2315-22. PubMed ID: 21680906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
